Topic Contents
Atherosclerosis
Need to Know
-
Trim the unhealthy fat
Protect your arteries by cutting meat, dairy fats, and foods containing trans fats out of your diet
-
Get to know tocotrienols
Take 200 mg a day of these potent antioxidants to slow down the build-up of plaque in your arteries
-
Take extra garlic
900 mg a day of standardized garlic powder can help slow down the process of hardening of the arteries
-
Lower your homocysteine levels
Reduce the blood levels of this potentially toxic substance by taking a daily B-vitamin combo containing folic acid (400 to 1,000 mcg), vitamin B12 (50 to 300 mcg), and vitamin B6 (10 to 50 mg)
About
About This Condition
Atherosclerosis is hardening of the arteries, a common disease of the major blood vessels characterized by fatty streaks along the vessel walls and by deposits of cholesterol and calcium.
Atherosclerosis of arteries supplying the heart is called coronary artery disease. It can restrict the flow of blood to the heart, which often triggers heart attacks—the leading cause of death in Americans and Europeans. Atherosclerosis of arteries supplying the legs causes a condition called intermittent claudication, which is characterized by pain in the legs after walking short distances.
People with elevated cholesterol levels are much more likely to have atherosclerosis than people with low cholesterol levels. Many important nutritional approaches to protecting against atherosclerosis are aimed at lowering serum cholesterol levels.
People with diabetes are also at very high risk for atherosclerosis, as are people with elevated triglycerides and high homocysteine.
Symptoms
Atherosclerosis is typically a silent disease until one of the many late-stage vascular manifestations intervenes. Some people with atherosclerosis may experience angina (chest pain) or intermittent claudication (leg cramps and pain) on exertion. Symptoms such as these develop gradually as the disease progresses.
Eating Right
The right diet is the key to managing many diseases and to improving general quality of life. For this condition, scientific research has found benefit in the following healthy eating tips.
| Recommendation | Why | Get started |
|---|---|---|
| Choose omega-6-rich foods |
Eating omega-6 fatty acids, found in corn, safflower, grapeseed, and sunflower oils, and in foods such as nuts and seeds, appears to protect against atherosclerosis and is associated with reduced heart disease risk. |
|
Choose omega-6-rich foodsA diet high in omega-6 fatty acids, found in certain vegetable oils such as corn, safflower, grapeseed, and sunflower oil, and in other foods such as nuts and seeds, appears to protect against atherosclerosis. Higher dietary intake or high body levels of omega-6 fatty acids has been associated with reduced coronary heart disease risk in numerous preliminary studies,1 and an analysis of several controlled trials found that replacing saturated fats in the diet with omega-6 fats reduces the risk of coronary heart disease by an average of 24%.2
|
||
| Eat a high-fiber diet | Eating foods high in fiber, especially oats, psyllium seeds, fruit, and beans, may lower cholesterol and reduce the risk of coronary heart disease. | |
Eat a high-fiber dietA systematic review of 20 years of research evaluated the association between dietary fiber and coronary heart disease.3 The meta-analysis portion of this review showed that whole grain foods are associated with a coronary heart disease risk reduction of about 26%. In general, the fibers most linked to the reduction of cholesterol levels are found in oats, psyllium seeds, fruit (pectin) and beans (guar gum).4 An analysis of many soluble fiber trials proves that a cholesterol-lowering effect exists, but the amount the cholesterol falls is quite modest.5 For unknown reasons, however, diets higher in insoluble fiber (found in whole grains and vegetables and mostly unrelated to cholesterol levels) have been reported to correlate better with protection against heart disease in both men and women.6 , 7 Some trials have used 20 grams of additional fiber per day for several months to successfully lower cholesterol.8
|
||
| Eat more complex carbs | Choose whole grains whenever possible as a diet high in refined carbs, such as white flour, white rice, and simple sugars, appears to increase the risk of coronary heart disease, especially in overweight women. | |
Eat more complex carbsEating a diet high in refined carbohydrates (e.g., white flour, white rice, simple sugars) appears to increase the risk of coronary heart disease, and thus of heart attacks, especially in overweight women.9 However, controlled trials of reducing refined carbohydrate intake to prevent heart disease have not been attempted to confirm these preliminary findings. |
||
| Go vegetarian | A pure vegetarian diet (no meat, poultry, dairy or eggs), combined with exercise and stress reduction, has been shown to decrease atherosclerosis. | |
Go vegetarianIndependent of their action on serum cholesterol, foods that contain high amounts of cholesterol—mostly egg yolks—can induce atherosclerosis.10 It makes sense to reduce the intake of egg yolks. However, eating eggs does not increase serum cholesterol as much as eating saturated fat, and eggs may not increase serum cholesterol at all if the overall diet is low in fat. A decrease in atherosclerosis resulting from a pure vegetarian diet (no meat, poultry, dairy or eggs), combined with exercise and stress reduction, has been proven by controlled medical research.11 |
||
| Skip the salt | Eating low or moderate amounts of salt may help reduce your risk of heart disease. | |
Skip the saltPreliminary evidence has suggested that excessive salt consumption is a risk factor for heart disease and death from heart disease in overweight people.12 Controlled trials are needed to confirm these observations.
|
||
| Try a low-fat diet | The most important dietary changes in protecting arteries from atherosclerosis include choosing alternatives to meat and dairy, and eating foods without trans fats. | |
Try a low-fat dietThe most important dietary changes in protecting arteries from atherosclerosis include avoiding meat and dairy fat and avoiding foods that contain trans fatty acids (many margarines, some vegetable oils, and many processed foods containing vegetable oils). Increasingly, the importance of avoiding trans fatty acids is being accepted by the scientific community.13 Leading researchers have recently begun to view the evidence linking trans fatty acids to markers for heart disease as “unequivocal.”14 |
||
| Try ALA | People who eat diets high in alpha-linolenic acid—found in canola oil and flaxseed products—have high blood levels of omega-3 fatty acids, which may protect against atherosclerosis. | |
Try ALAPeople who eat diets high in alpha-linolenic acid (ALA), which is found in canola oil and flaxseed products, have higher blood levels of omega-3 fatty acids than those consuming lower amounts,15 , 16 which may confer some protection against atherosclerosis. In 1994, researchers conducted a study in people with a history of heart disease, using what they called the “Mediterranean” diet.17 The diet differed significantly from what people from Mediterranean countries actually eat, in that it contained little olive oil. Instead, the diet included a special margarine high in ALA. Those people assigned to the Mediterranean diet had a remarkable 70% reduced risk of dying from heart disease compared with the control group during the first 27 months. Similar results were also confirmed after almost four years.18 The diet was high in beans and peas, fish, fruit, vegetables, bread, and cereals, and low in meat, dairy fat, and eggs. Although the authors believe that the high ALA content of the diet was partly responsible for the surprising outcome, other aspects of the diet may have been partly or even totally responsible for decreased death rates. Therefore, the success of the Mediterranean diet does not prove that ALA protects against heart disease.19 |
||
Supplements
What Are "Star" Ratings?
Reliable and relatively consistent scientific data showing a substantial health benefit.
Contradictory, insufficient, or preliminary studies suggesting a health benefit or minimal health benefit.
For an herb, supported by traditional use but minimal or no scientific evidence. For a supplement, little scientific support.
Our proprietary “Star-Rating” system was developed to help you easily understand the amount of scientific support behind each supplement in relation to a specific health condition. While there is no way to predict whether a vitamin, mineral, or herb will successfully treat or prevent associated health conditions, our unique ratings tell you how well these supplements are understood by the medical community, and whether studies have found them to be effective for other people.
For over a decade, our team has combed through thousands of research articles published in reputable journals. To help you make educated decisions, and to better understand controversial or confusing supplements, our medical experts have digested the science into these three easy-to-follow ratings. We hope this provides you with a helpful resource to make informed decisions towards your health and well-being.
| Supplement | Amount | Why |
|---|---|---|
|
Garlic
|
900 mg daily of a powder standardized for 0.6% allicin |
Garlic has been shown to slow down the process of the arteries hardening. Aged garlic extract has been shown to prevent oxidation of LDL ("bad") cholesterol, a significant factor in atherosclerosis development.
|
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Omega-6 Fatty Acids
|
Follow label instructions |
Though the effect has not been studied with supplements, an analysis of several controlled trials found that replacing saturated fats in the diet with omega-6 fats reduces the risk of coronary heart disease.
|
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Fish Oil
|
3 to 6 grams fish oil daily, containing at least 30% omega-3 fatty acids |
Fish oil may reduce risk factors for atherosclerosis and heart disease. One trial showed that people who took fish oil had a slowing of the progression of their arterial plaque and had a decrease in cardiovascular events such as heart attack and stroke.
|
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Folic Acid
|
Consult a qualified healthcare practitioner |
Blood levels of an amino acid called homocysteine have been linked to atherosclerosis and heart disease in most research. Taking folic acid may help lower homocysteine levels. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Horny Goat Weed
|
5 grams three times per day |
Horny goat weed has historically been used in people with symptoms caused by hardening of the arteries, in particular those recovering from strokes. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Niacin (Vitamin B3)
|
2,000 mg per day (only under a doctor's supervision) |
In a preliminary trial, doctor-supervised supplementation with extended-release niacin in combination with a cholesterol-lowering statin drug appeared to reverse atherosclerosis of the carotid arteries (the arteries that supply blood to the brain).
|
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Selenium
|
100 mcg daily |
Some doctors recommend that people with atherosclerosis supplement with selenium, which has been shown in one study to help reduce the risk of death from heart disease. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Tocotrienols
|
200 mg daily |
Tocotrienols are potent antioxidants that may help slow down the build-up of plaque in the arteries. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Vitamin C
|
250 mg twice per day |
Supplementing with vitamin C may help reverse the progression of atherosclerosis and protect against heart disease. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Vitamin K
(Vitamin K1, for coronary calcification ) |
500 mcg per day of vitamin K1 |
In a double-blind trial, supplementing with vitamin K1 for three years appeared to slow the rate of progression of coronary artery calcification in seniors. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Betaine (Trimethylglycine)
|
Refer to label instructions |
For the few cases in which vitamin B6, vitamin B12, and folic acid fail to normalize homocysteine, adding betaine (trimethylglycine) may be effective. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Bilberry
|
Refer to label instructions |
Bilberry has been shown to prevent platelet aggregation. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Butcher’s Broom
|
Refer to label instructions |
Butcher’s broom exerts effects that protect arteries. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Chondroitin Sulfate
|
Refer to label instructions |
Preliminary research shows that chondroitin sulfate may prevent atherosclerosis and may also prevent heart attacks in people who already have atherosclerosis. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Evening Primrose Oil
|
Refer to label instructions |
Taking evening primrose oil has been shown to lower cholesterol in double-blind research. Lowering cholesterol levels should in turn reduce the risk of atherosclerosis. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Ginger
|
Refer to label instructions |
Supplementing with ginger may reduce platelet stickiness. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Ginkgo
|
Refer to label instructions |
The herb Ginkgo biloba may reduce atherosclerosis risk by stopping platelets from sticking together too much. It also increases blood circulation to the brain, arms, and legs.
|
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Lycopene
|
Refer to label instructions |
The carotenoid lycopene, present in high amounts in tomatoes, may help prevent atherosclerosis. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Peony
|
Refer to label instructions |
Peony has been shown to prevent platelet aggregation. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Quercetin
|
Refer to label instructions |
Quercetin, a flavonoid, protects LDL cholesterol from damage. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Resveratrol
|
Refer to label instructions |
Studies have found that red wine, which contains resveratrol, lowers risk of death from heart disease. Its antioxidant activity and effect on platelets leads some researchers believe that it is the protective agent in red wine.
|
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Rice Protein
|
Refer to label instructions |
Though not yet proven in clinical research, animal studies suggest that rice protein–based diets result in less buildup of atherosclerotic plaque compared with animal protein–based diets.
|
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Rosemary
|
Refer to label instructions |
Rosemary is traditionally reputed to have a positive effect on atherosclerosis. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Shelled Hemp Seed
|
Refer to label instructions |
Shelled hemp seed or its oil may theoretically be useful for people with atherosclerosis due to its essential fatty acid content. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Turmeric
|
Refer to label instructions |
Turmeric’s active compound curcumin has shown potent anti-platelet activity in preliminary studies. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Vitamin B12
|
Refer to label instructions |
Blood levels of the amino acid homocysteine have been linked to atherosclerosis and heart disease in most research. Taking vitamin B12 may help lower homocysteine levels. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Vitamin B6
|
Refer to label instructions |
Blood levels of the amino acid homocysteine have been linked to atherosclerosis and heart disease in most research. Taking vitamin B6 may help lower homocysteine levels. |
|
||
| Supplement | Amount | Why |
|---|---|---|
|
Vitamin E
|
100 to 200 IU daily |
Vitamin E is an antioxidant that protects LDL cholesterol from oxidative damage and has been linked to heart disease prevention. Many doctors recommend supplementing with vitamin E to lower the risk of atherosclerosis and heart attacks. |
|
||
References
1. Harris WS, Mozaffarian D, Rimm E, et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation 2009;119:902-7 [review].
2. Gordon DJ. Lowering cholesterol and total mortality. In: Rifkin BM, ed. Lowering cholesterol in high-risk individuals and populations. New York, NY: Marcel Dekker, Inc; 1995:33– 48.
3. Anderson JW, Hanna TJ, Peng X, Kryscio RJ. Whole grain foods and heart disease risk. J Am Coll Nutr 2000;19(3 Suppl):291S–299S.
4. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999;69:30–42.
5. Brown L, Rosner B, Willett WW, Sacks FM. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr 1999;69:30–42.
6. Jenkins DJA, Kendall CWC, Ransom TPP. Dietary fiber, the evolution of the human diet and coronary heart disease. Nutr Res 1998;18:633–52 [review].
7. Wolk A, Manson JE, Stampfer MJ, et al. Long-term intake of dietary fiber and decreased risk of coronary hart disease among women. JAMA 1999;281:1998–2004.
8. Knopp RH, Superko HR, Davidson M, et al. Long-term blood cholesterol-lowering effects of a dietary fiber supplement. Am J Prev Med 1999;17:18–23.
9. Liu S, Willett WC, Stampfer MJ, et al. A prospective study of dietary glycemic load, carbohydrate intake, and risk of coronary heart disease in US women. Am J Clin Nutr 2000;71:1455–61.
10. Raloff J. Oxidized lipids: a key to heart disease? Sci News 1985;127:278.
11. Ornish D, Brown SE, Scherwitz LW, et al. Can lifestyle changes reverse coronary heart disease? Lancet 1990;336:129–33.
12. He J, Ogden LG, Vupputuri S, et al. Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults. JAMA 1999;282:2027–34.
13. Nelson GJ. Dietary fat, trans fatty acids, and risk of coronary heart disease. Nutr Rev 1998;250–2.
14. Ascherio A, Willett WC. Health effects of trans fatty acids. Am J Clin Nutr 1997;66(suppl):1006S–10S [review].
15. Li D, Sinclair A, Wilson A, et al. Effect of dietary alpha-linolenic acid on thrombotic risk factors in vegetarian men. Am J Clin Nutr 1999;69:872–82.
16. Cunnane SC, Hamadeh MJ, Liede AC, et al. Nutritional attributes of traditional flaxseed in healthy young adults. Am J Clin Nutr 1994;61:62–8.
17. De Lorgeril M, Renaud S, Mamelle N, et al. Mediterranean alpha-linolenic-rich diet in secondary prevention of coronary heart disease. Lancet 1994;343:1454–9.
18. De Lorgeril M, Salen P, Martin J-L, et al. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction. Final report of the Lyon Diet Heart Study. Circulation 1999;99:779–85.
19. Rice RD. Mediterranean diet. Lancet 1994;344:893–4 [letter].
20. Koscienlny J, Klüßendorf D, Latza R, et al. The anti-atherosclerotic effect of Allium sativum. Atherosclerosis 1999;144:237–49.
21. Neil HAW, Silagy CA, Lancaster T, et al. Garlic powder in the treatment of moderate hyperlipidaemia: A controlled trial and a meta-analysis. J R Coll Phys 1996;30:329–34.
22. McCrindle BW, Helden E, Conner WT. Garlic extract therapy in children with hypercholesterolemia. Arch Pediatr Adolesc Med 1998;152:1089–94.
23. Isaacsohn JL, Moser M, Stein EA, et al. Garlic powder and plasma lipids and lipoproteins. Arch Intern Med 1998;158:1189–94.
24. Berthold HK, Sudhop T, von Bergmann K. Effect of a garlic oil preparation on serum lipoproteins and cholesterol metabolism. JAMA 1998;279:1900–2.
25. Lawson L. Garlic oil for hypercholesterolemia–negative results. Quart Rev Natural Med 1998;Fall:185–6.
26. Garlic powder for hyperlipidemia–analysis of recent negative results. Quart Rev Natural Med 1998;Fall:187–9.
27. Kiesewetter H, Jung F, Pindur G, et al. Effect of garlic on thrombocyte aggregation, microcirculation and other risk factors. Int J Pharm Ther Toxicol 1991;29(4):151–5.
28. Srivastava KC, Tyagi OD. Effect of a garlic derived principle (ajoene) on aggregation and arachidonic acid metabolism in human blood platelets. Prostagl Leukotr Ess Fatty Acids 1993;49:587–95.
29. Munday JS, James KA, Fray LM, et al. Daily supplementation with aged garlic extract, but not raw garlic, protects low density lipoprotein against in vitro oxidation. Atherosclerosis 1999;143:399–404.
30. Kiesewetter H, Jung F, Mrowietz C, et al. Effects of garlic on blood fluidity and fibrinolytic activity: A randomised, placebo-controlled, double-blind study. Br J Clin Pract Suppl 1990;69:24–9.
31. Jung F, Mrowietz C, Kiesewetter H, Wenzel E. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneimittelforschung 1990;40:589–93.
32. Phelps S, Harris WS. Garlic supplementation and lipoprotein oxidation susceptibility. Lipids 1993;28(5):475–7.
33. Yan LJ, Droy-Lefaix MT, Packer L. Ginkgo biloba extract (EGb 761) protects human low density lipoproteins against oxidative modification mediated by copper. Biochem Biophys Res Comm 1995;212:360–6.
34. Singh K, Chander R, Kapoor NK. Guggulsterone, a potent hypolipidaemic, prevents oxidation of low density lipoprotein. Phytother Res 1997;11:291–4.
35. Harris WS, Mozaffarian D, Rimm E, et al. Omega-6 fatty acids and risk for cardiovascular disease: a science advisory from the American Heart Association Nutrition Subcommittee of the Council on Nutrition, Physical Activity, and Metabolism; Council on Cardiovascular Nursing; and Council on Epidemiology and Prevention. Circulation 2009;119:902-7 [review].
36. Gordon DJ. Lowering cholesterol and total mortality. In: Rifkin BM, ed. Lowering cholesterol in high-risk individuals and populations. New York, NY: Marcel Dekker, Inc; 1995:33– 48.
37. Ando M, Sanaka T, Nihei H. Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients. J Am Soc Nephrol 1999;10:2177–84.
38. Olszewski AJ, McCully KS. Fish oil decreases serum homocysteine in hyperlipemic men. Coron Artery Dis 1993;4:53–60.
39. Phillipson BE, Rothrock DW, Connor WE, et al. Reduction of plasma lipids, lipoproteins, and apoproteins by dietary fish oils in patients with hypertriglyceridemia. N Engl J Med 1985;312:1210–6.
40. Haglund O, Wallin R, Luostarinen R, Saldeen T. Effects of a new fluid fish oil concentrate, ESKIMO-3, on triglycerides, cholesterol, fibrinogen and blood pressure. J Intern Med 1990;227:347–53.
41. Haglund O, Luostarinen R, Wallin W, Saldeen T. Effects of fish oil on triglycerides, lipoprotein(a), atherogenic index and fibrinogen. Influence of the degree of purification of the oil. Nutr Res 1992;12:455–68.
42. Haglund O, Luostarinen R, Wallin R, et al. The effects of fish oil on triglycerides, cholesterol, fibrinogen and malondialdehyde in humans supplemented with vitamin E. J Nutr 1991;121:165–9.
43. Leng GC, Lee AJ, Fowkes FG, et al. Randomized controlled trial of gamma-linolenic acid and eicosapentaenoic acid in peripheral arterial disease. Clin Nutr 1998;17:265–71.
44. Leaf A, Jorgensen MB, Jacobs AK, et al. Do fish oils prevent restenosis after coronary angioplasty? Circulation 1994;90:2248–57.
45. Sacks FM, Stone PH, Gibson CM, et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol 1995;25:1492–8.
46. von Schacky C, Angerer P, Kothny W, et al. The effect of dietary omega-3 fatty acids on coronary atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999;130:554–62.
47. Sacks FM, Stone PH, Gibson CM, et al. Controlled trial of fish oil for regression of human coronary atherosclerosis. HARP Research Group. J Am Coll Cardiol 1995;25:1492–8.
48. Stampfer MJ, Malinow R, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877–81.
49. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiobascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159:1077–80.
50. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation 1998;98:204–10.
51. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation 1998;98:196–9 [editorial/review].
52. Stolzen berg-Solomon RZ, Miller ER III, Maguire MG, et al. Association of dietary protein intake and coffee consumption with serum homocysteine concentrations in an older population. Am J Clin Nutr 1999;69:467–75.
53. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–8.
54. Ubbink JB, Hayward WJ, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–33.
55. Manson JB, Miller JW. The effects of vitamin B12, B6, and folate on blood homocysteine levels. Ann NY Acad Sci 1992;669:197–204 [review].
56. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation 1998;98:204–10.
57. Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Am J Hypertens 2000;13:105–10.
58. Till U, Rohl P, Jentsch A, et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. Atherosclerosis2005;181:131–5.
59. Franken DG, Boers GHJ, Blom HJ, et al. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994;14:465–70.
60. Ubbink JB, Vermaak WJH, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–33.
61. Ubbink JB, van der Merwe A, Vermaak WJH, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Investig 1993;71:993–8.
62. Tan X, Weng W. Efficacy of epimedium compound pills in the treatment of the aged patients with kidney deficiency syndrome of ischemic cardio-cerebral vascular diseases. Hunan Yi Ke Da Xue Xue Bao 1998;23:450–2 [in Chinese].
63. Taylor AJ, Villines TC, Stanek EJ, et al. Extended-release niacin or ezetimibe and carotid intima-media thickness. N Engl J Med 2009 [E-pub ahead of print].
64. Salonen JT et al. Association between cardiovascular death and myocardial infarction and serum selenium in a matched-pair longitudinal study. Lancet 1982;ii:175.
65. Shamberger RJ, Willis CE. Epidemiological studies on selenium and heart disease. Fed Proc 1976;35:578 [abstract #2061].
66. Korpela H, Kumpulainen J, Jussila E, et al. Effect of selenium supplementation after acute myocardial infarction. Res Comm Chem Pathol Pharmacol 1989; 65:249–52.
67. Suarna C, Hood RL, Dean RT, Stocker R. Comparative antioxidant activity of tocotrienols and other natural lipid-soluble antioxidants in a homogeneous system, and in rat and human lipoproteins. Biochim Biophys Acta 1993;1166:163–70.
68. Tomeo AC, Geller M, Watkins TR, et al. Antioxidant effects of tocotrienols in patients with hyperlipidemia and carotid stenosis. Lipids 1995;30:1179–83.
69. Chambers JC, McGregor A, Jean-Marie J, et al. Demonstration of rapid onset vascular endothelial dysfunction after hyperhomocysteinemia. An effect reversible with vitamin C therapy. Circulation 1999;99:1156–60.
70. Frei B. Ascorbic acid protects lipids in human plasma and low-density lipoprotein against oxidative damage. Am J Clin Nutr 1991;54:1113S–8S.
71. Balz F. Antioxidant Vitamins and Heart Disease. Presented at the 60th Annual Biology Colloquium, Oregon State University, February 25, 1999.
72. Salonen JT, Nyyssönen K, Salonen R, et al. Antioxidant supplementation in atherosclerosis prevention (ASAP) study: a randomized trial of the effect of vitamin E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000;248:177–86.
73. Shea MK, O'Donnell CJ, Hoffmann U, et al. Vitamin K supplementation and progression of coronary artery calcium in older men and women. Am J Clin Nutr 2009;89:1799–807.
74. Stampfer MJ, Malinow R, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877–81.
75. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiobascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159:1077–80.
76. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation 1998;98:204–10.
77. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation 1998;98:196–9 [editorial/review].
78. Stolzen berg-Solomon RZ, Miller ER III, Maguire MG, et al. Association of dietary protein intake and coffee consumption with serum homocysteine concentrations in an older population. Am J Clin Nutr 1999;69:467–75.
79. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–8.
80. Ubbink JB, Hayward WJ, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–33.
81. Manson JB, Miller JW. The effects of vitamin B12, B6, and folate on blood homocysteine levels. Ann NY Acad Sci 1992;669:197–204 [review].
82. Franken DG, Boers GHJ, Blom HJ, et al. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994;14:465–70.
83. Ubbink JB, Vermaak WJH, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–33.
84. Ubbink JB, van der Merwe A, Vermaak WJH, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Investig 1993;71:993–8.
85. Srivastava R, Dikshit M, Srimal RC, Dhawan BN. Anti-thrombotic action of curcumin. Throm Res 1985;404:413–7.
86. Srivastava KC, Bordia A, Verma SK. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prost Leuk Essen Fat Acids. 1995;52:223–7.
87. Pulliero G, Montin S, et al. Ex vivo study of the inhibitory effects of Vaccinium myrtillus (bilberry) anthocyanosides on human platelet aggregation. Fitoterapia 1989;60:69–75.
88. Liu J. Effect of Paeonia obovata 801 on metabolism of thromboxane B2 and arachidonic acid and on platelet aggregation in patients with coronary heart disease and cerebral thrombosis. Chin Med J 1983;63:477–81 [in Chinese].
89. Felix W, Schmidt Y, Nieberle J. Protective effect of Ruscus extract against injury of vascular endothelium and vascular smooth muscle caused by ethracrynic acid. Int Angiol 1983;3:77.
90. Morrison LM, Branwood AW, Ershoff BH, et al. The prevention of coronary arteriosclerotic heart disease with chondroitin sulfate A: Preliminary report. Exp Med Surg 1969;27:278–89.
91. Morrison LM, Enrick NL. Coronary heart disease: Reduction of death rate by chondroitin sulfate A. Angiology 1973;24:269–82.
92. Boberg M, Vessby B, Selinus I. Effects of dietary supplementation with n-6 and n-3 long-chain polyunsaturated fatty acids on serum lipoproteins and platelet function in hypertriglcyeridaemic patients. Acta Med Scand 1986;220:153–60.
93. Horrobin DF, Manku MS. How do polyunsaturated fatty acids lower plasma cholesterol levels? Lipids 1983;558–62.
94. Morrison LM, Branwood AW, Ershoff BH, et al. The prevention of coronary arteriosclerotic heart disease with chondroitin sulfate A: Preliminary report. Exp Med Surg 1969;27:278–89.
95. Morrison LM, Enrick NL. Coronary heart disease: Reduction of death rate by chondroitin sulfate A. Angiology 1973;24:269–82.
96. Bordia A, Verma SK, Srivastava KC. Effect of ginger (Zingiber officinale Rosc) and fenugreek (Trigonella foenumgraceum L) on blood lipids, blood sugar, and platelet aggregation in patients with coronary artery disease. Prostagland Leukotrienes Essential Fatty Acids 1997;56:379–84.
97. Lumb AB. Effect of dried ginger on human platelet function. Thromb Haemost 1994;7:110–1.
98. Janssen PL, Meyboom S, van Staveren WA, et al. Consumption of ginger (Zingiber officinale Roscoe) does not affect ex vivo platelet thromboxane production in humans. Eur J Clin Nutr 1996;50:772–4.
99. Braquet P, Touqui L, Shen TS, Vargaftig BB. Perspectives in platelet activating factor research. Pharmacol Rev 1987;39:97–210.
100. Brown DJ. Herbal Prescriptions for Better Health. Rocklin, CA: Prima Publishing, 1996, 119–28.
101. Kiesewetter H, Jung F, Mrowietz C, et al. Effects of garlic on blood fluidity and fibrinolytic activity: A randomised, placebo-controlled, double-blind study. Br J Clin Pract Suppl 1990;69:24–9.
102. Jung F, Mrowietz C, Kiesewetter H, Wenzel E. Effect of Ginkgo biloba on fluidity of blood and peripheral microcirculation in volunteers. Arzneimittelforschung 1990;40:589–93.
103. Phelps S, Harris WS. Garlic supplementation and lipoprotein oxidation susceptibility. Lipids 1993;28(5):475–7.
104. Yan LJ, Droy-Lefaix MT, Packer L. Ginkgo biloba extract (EGb 761) protects human low density lipoproteins against oxidative modification mediated by copper. Biochem Biophys Res Comm 1995;212:360–6.
105. Singh K, Chander R, Kapoor NK. Guggulsterone, a potent hypolipidaemic, prevents oxidation of low density lipoprotein. Phytother Res 1997;11:291–4.
106. Klipstein-Grobusch K, Launer LJ, Geleijnse JM, et al. Serum carotenoids and atherosclerosis. The Rotterdam Study. Atherosclerosis 2000;148:49–56.
107. Srivastava R, Dikshit M, Srimal RC, Dhawan BN. Anti-thrombotic action of curcumin. Throm Res 1985;404:413–7.
108. Srivastava KC, Bordia A, Verma SK. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prost Leuk Essen Fat Acids. 1995;52:223–7.
109. Pulliero G, Montin S, et al. Ex vivo study of the inhibitory effects of Vaccinium myrtillus (bilberry) anthocyanosides on human platelet aggregation. Fitoterapia 1989;60:69–75.
110. Liu J. Effect of Paeonia obovata 801 on metabolism of thromboxane B2 and arachidonic acid and on platelet aggregation in patients with coronary heart disease and cerebral thrombosis. Chin Med J 1983;63:477–81 [in Chinese].
111. Ronzio RA. Antioxidants, nutraceuticals and functional foods. Townsend Letter for Doctors and Patients 1996;Oct:34–5 [review].
112. Hertog MGL, Feskens EJM, Hollman PCH, et al. Dietary antioxidant flavonoids and risk of coronary heart disease: the Zutphen Elderly Study. Lancet 1993;342:1007–11.
113. Hertog MGL, Kromhout D, Aravanis C, et al. Flavonoid intake and long-term risk of coronary heart disease and cancer in the Seven Countries Study. Arch Intern Med 1995;155:381–6.
114. Knekt P, Jarvinen R, Reunanen A, Maatela J. Flavonoid intake and coronary mortality in Finland: a cohort study. BMJ 1996;312:478–81.
115. Rimm EB, Katan MB, Ascherio A, et al. Relation between intake of flavonoids and risk for coronary heart disease in male health professionals. Ann Intern Med 1996; 125:384–9.
116. Hertog MGL, Sweetnam PM, Fehily AM, et al. Antioxidant flavonols and ischemic heart disease in a Welsh population of men: the Caerphilly Study. Am J Clin Nutr 1997;65:1489–94.
117. Bertelli AA, Giovanninni L, Bernini W, et al. Antiplatelet activity of cis-resveratrol. Drugs Exp Clin Res 1996;22(2):61–3.
118. Chen CK, Pace-Asciak. CR. Vasorelaxing activity of resveratrol and quercetin in isolated rat aorta. Gen Pharm 1996;27(2):363–6.
119. Pace-Asciak CR, Rounova O, Hahn SE, et al. Wines and grape juices as modulators of platelet aggregation in healthy human subjects. Clin Chim Acta 1996;246(1–2):163–82.
120. Burris RL, Xie CH, Thampi P, et al. Dietary rice protein isolate attenuates atherosclerosis in apoE-deficient mice by upregulating antioxidant enzymes. Atherosclerosis 2010;212:107-15.
121. Burris RL, Xie CH, Thampi P, et al. Dietary rice protein isolate attenuates atherosclerosis in apoE-deficient mice by upregulating antioxidant enzymes. Atherosclerosis 2010;212:107-15.
122. Yang L, Kadowaki M. Effects of rice proteins from two cultivars, Koshihikari and Shunyo, on hepatic cholesterol secretion by isolated perfused livers of rats fed cholesterol-enriched diets. Ann Nutr Metab 2009;54:283-90.
123. Ronis MJ, Badeaux J, Chen Y, Badger TM. Rice protein isolate improves lipid and glucose homeostasis in rats fed high fat/high cholesterol diets. Exp Biol Med (Maywood) 2010;235:1102-13.
124. Felix W, Schmidt Y, Nieberle J. Protective effect of Ruscus extract against injury of vascular endothelium and vascular smooth muscle caused by ethracrynic acid. Int Angiol 1983;3:77.
125. Fitzsimmons S. Hemp seed oil: Fountain of youth? Br J Phytother 1998;5:90–6.
126. Srivastava R, Dikshit M, Srimal RC, Dhawan BN. Anti-thrombotic action of curcumin. Throm Res 1985;404:413–7.
127. Srivastava KC, Bordia A, Verma SK. Curcumin, a major component of food spice turmeric (Curcuma longa) inhibits aggregation and alters eicosanoid metabolism in human blood platelets. Prost Leuk Essen Fat Acids. 1995;52:223–7.
128. Pulliero G, Montin S, et al. Ex vivo study of the inhibitory effects of Vaccinium myrtillus (bilberry) anthocyanosides on human platelet aggregation. Fitoterapia 1989;60:69–75.
129. Liu J. Effect of Paeonia obovata 801 on metabolism of thromboxane B2 and arachidonic acid and on platelet aggregation in patients with coronary heart disease and cerebral thrombosis. Chin Med J 1983;63:477–81 [in Chinese].
130. Stampfer MJ, Malinow R, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877–81.
131. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiobascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159:1077–80.
132. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation 1998;98:204–10.
133. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation 1998;98:196–9 [editorial/review].
134. Stolzen berg-Solomon RZ, Miller ER III, Maguire MG, et al. Association of dietary protein intake and coffee consumption with serum homocysteine concentrations in an older population. Am J Clin Nutr 1999;69:467–75.
135. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–8.
136. Ubbink JB, Hayward WJ, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–33.
137. Manson JB, Miller JW. The effects of vitamin B12, B6, and folate on blood homocysteine levels. Ann NY Acad Sci 1992;669:197–204 [review].
138. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation 1998;98:204–10.
139. Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Am J Hypertens 2000;13:105–10.
140. Till U, Rohl P, Jentsch A, et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. Atherosclerosis2005;181:131–5.
141. Franken DG, Boers GHJ, Blom HJ, et al. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994;14:465–70.
142. Ubbink JB, Vermaak WJH, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–33.
143. Ubbink JB, van der Merwe A, Vermaak WJH, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Investig 1993;71:993–8.
144. Stampfer MJ, Malinow R, Willett WC, et al. A prospective study of plasma homocyst(e)ine and risk of myocardial infarction in US physicians. JAMA 1992;268:877–81.
145. Bostom AG, Silbershatz H, Rosenberg IH, et al. Nonfasting plasma total homocysteine levels and all-cause and cardiobascular disease mortality in elderly Framingham men and women. Arch Intern Med 1999;159:1077–80.
146. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation 1998;98:204–10.
147. Kuller LH, Evans RW. Homocysteine, vitamins, and cardiovascular disease. Circulation 1998;98:196–9 [editorial/review].
148. Stolzen berg-Solomon RZ, Miller ER III, Maguire MG, et al. Association of dietary protein intake and coffee consumption with serum homocysteine concentrations in an older population. Am J Clin Nutr 1999;69:467–75.
149. Selhub J, Jacques PF, Wilson PW, et al. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 1993;270:2693–8.
150. Ubbink JB, Hayward WJ, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–33.
151. Manson JB, Miller JW. The effects of vitamin B12, B6, and folate on blood homocysteine levels. Ann NY Acad Sci 1992;669:197–204 [review].
152. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins. Circulation 1998;98:204–10.
153. Hackam DG, Peterson JC, Spence JD. What level of plasma homocyst(e)ine should be treated? Am J Hypertens 2000;13:105–10.
154. Till U, Rohl P, Jentsch A, et al. Decrease of carotid intima-media thickness in patients at risk to cerebral ischemia after supplementation with folic acid, vitamins B6 and B12. Atherosclerosis2005;181:131–5.
155. Franken DG, Boers GHJ, Blom HJ, et al. Treatment of mild hyperhomocysteinemia in vascular disease patients. Arterioscler Thromb 1994;14:465–70.
156. Ubbink JB, Vermaak WJH, van der Merwe A, et al. Vitamin requirements for the treatment of hyperhomocysteinemia in humans. J Nutr 1994;124:1927–33.
157. Ubbink JB, van der Merwe A, Vermaak WJH, Delport R. Hyperhomocysteinemia and the response to vitamin supplementation. Clin Investig 1993;71:993–8.
158. Belcher JD, Balla J, Balla G, et al. Vitamin E, LDL, and endothelium: Brief oral vitamin supplementation prevents oxidized LDL-mediated vascular injury in vitro. Arterioscler Thromb 1993;13:1779–89.
159. Stephens NG, Parsons A, Schofield PM, et al. Randomised controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781–6.
160. Rimm E. Micronutrients, Coronary Heart disease and cancer: Should we all be on supplements? Presented at the 60th Annual Biology Colloquium, Oregon State University, February 25, 1999.
161. Salonen JT, Nyyssönen K, Salonen R, et al. Antioxidant supplementation in atherosclerosis prevention (ASAP) study: a randomized trial of the effect of vitamin E and C on 3-year progression of carotid atherosclerosis. J Intern Med 2000;248:177–86.
Last Review: 08-17-2011
Copyright © 2011 Aisle7. All rights reserved. www.Aisle7.net
Learn more about Aisle7, the company.
The information presented in Aisle7 is for informational purposes only. It is based on scientific studies (human, animal, or in vitro), clinical experience, or traditional usage as cited in each article. The results reported may not necessarily occur in all individuals. Self-treatment is not recommended for life-threatening conditions that require medical treatment under a doctor's care. For many of the conditions discussed, treatment with prescription or over the counter medication is also available. Consult your doctor, practitioner, and/or pharmacist for any health problem and before using any supplements or before making any changes in prescribed medications. Information expires June 2013.
This information does not replace the advice of a doctor. Healthwise, Incorporated disclaims any warranty or liability for your use of this information. Your use of this information means that you agree to the Terms of Use. How this information was developed to help you make better health decisions.
Healthwise, Healthwise for every health decision, and the Healthwise logo are trademarks of Healthwise, Incorporated.
